Skip to Main Content


Yale researchers have introduced countless medical and health advances over the last century, including the first success with antibiotics in the United States and the first use of chemotherapy to treat cancer. University scientists have been responsible for the identification of Lyme disease and the discovery of genes responsible for high blood pressure, osteoporosis, dyslexia, and Tourette's syndrome, among other disorders. Early work on the artificial heart and the creation of the first insulin pump took place at Yale, as did seminal discoveries about how the cell and its components function at the molecular level. Today, research activities take place in a wide range of departments, programs, and centers.

A total of $663 million in sponsored research funding was received and spent at the Yale School of Medicine during FY19. The school ranked sixth among medical schools receiving research funding from the NIH in FY19 and twelfth in NIH grants per faculty member.

The School of Medicine has extraordinary strength in the basic sciences and consistently ranks in the top handful of medical schools receiving funding from the National Institutes of Health.

The section of Endocrine Surgery has strong teaching, research and clinical missions at its foundation. The faculty is composed of active clinical surgeons involved in a busy surgical practice who are dedicated to pursuing clinical, translational, basic science research, as well as to developing new teaching modalities in the field of endocrine surgery. The section has strong multidisciplinary clinical and research collaboration with the departments of Medical Endocrinology, Pathology, Radiology and Genetics within the Yale School of Medicine.

The surgical clinical volume has risen significantly over the last few years, as referrals of patients with complex endocrine and oncologic problems have increased. This increase in the number and complexity of cases has placed our section on the world map in cutting-edge international clinical trials for advanced or metastatic thyroid cancer, thus offering new therapies and hope for patients who, until now, would have had no good options for treatment.